Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Genflow Biosciences Plc ( (GB:GENF) ) is now available.
Genflow Biosciences Plc has raised £340,000 through the issuance of 40 million new ordinary shares to CEO Eric Leire, who will direct these shares to an institution for immediate resale. This strategic move, accompanied by the issuance of warrants, provides Genflow with essential working capital to continue its dog study and aligns long-term interests, while awaiting a grant payment from the Wallonia region. The transaction increases the company’s total voting rights to 493,547,942 shares, impacting shareholder calculations under FCA rules.
More about Genflow Biosciences Plc
Genflow Biosciences Plc, founded in 2020 and headquartered in the UK with R&D facilities in Belgium, is a biotechnology company focused on developing gene therapies to slow down the aging process. Their lead compound, GF-1002, aims to promote longer and healthier lives by delivering a centenarian variant of the SIRT6 gene, showing promising preclinical results. The company is also exploring the potential of GF-1002 in treating MASH, a prevalent chronic liver disease.
Average Trading Volume: 7,364,834
Technical Sentiment Signal: Buy
Learn more about GENF stock on TipRanks’ Stock Analysis page.